{"DataElement":{"publicId":"2597236","version":"1","preferredName":"Agent Intravenous Administered Type","preferredDefinition":"the type of agent that is injected into a blood vessel of a patient.","longName":"AGT_IV_ADMIN_TP","context":"NIDCR","contextVersion":"1","DataElementConcept":{"publicId":"2597230","version":"1","preferredName":"Agent Intravenous Administered","preferredDefinition":"information related to the injection into a blood vessel of an agent or drug to a patient.","longName":"AGT_IV_ADM","context":"NIDCR","contextVersion":"1","ObjectClass":{"publicId":"2223333","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B10F2-76A7-2830-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2597228","version":"1","preferredName":"Intravenous Administered","preferredDefinition":"(in-tra-VEE-nus) IV. Within a blood vessel.:Given.","longName":"C13346:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous","conceptCode":"C13346","definition":"Into or within a vein. Intravenous usually refers to a way of giving a drug or other substance through a needle or tube inserted into a vein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2973E4E5-FD68-0AB5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ONEDATA","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2973E581-50C4-0AC5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2597231","version":"1","preferredName":"Agent Intravenous Administration Type","preferredDefinition":"the type of agent injection administered.","longName":"AGT_IV_ADMIN_TP","context":"NIDCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Aredia or Pamidronate","valueDescription":"Pamidronate Disodium","ValueMeaning":{"publicId":"2576642","version":"1","preferredName":"Pamidronate Disodium","longName":"2576642","preferredDefinition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamidronate Disodium","conceptCode":"C1345","definition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29750180-C637-0EEB-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Bonefos and Ostac or Clodronate","valueDescription":"Clodronate Disodium","ValueMeaning":{"publicId":"2597233","version":"1","preferredName":"Clodronate Disodium","longName":"2597233","preferredDefinition":"A drug used as treatment for hypercalcemia (abnormally high levels of calcium in the blood) and for cancer that has spread to the bone (bone metastases). It may decrease pain, the risk of fractures, and the development of new bone metastases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clodronate Disodium","conceptCode":"C1418","definition":"The disodium salt of a nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29750184-344E-0EED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29750184-3466-0EED-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Boniva or Ibandronate","valueDescription":"Ibandronate Sodium","ValueMeaning":{"publicId":"2597181","version":"1","preferredName":"Ibandronate Sodium","longName":"2597181","preferredDefinition":"The sodium salt form of ibandronate, a synthetic nitrogen-containing bisphosphonate.  Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibandronate Sodium","conceptCode":"C1670","definition":"The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972C181-8505-54D4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29750184-3472-0EED-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Didronel or Etidronate","valueDescription":"Etidronate Disodium","ValueMeaning":{"publicId":"2597183","version":"1","preferredName":"Etidronate Disodium","longName":"2597183","preferredDefinition":"A synthetic therapeutic diphosphonate analogue of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, etidronate disodium differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis.  This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption.  Etidronate may also directly stimulate bone formation by osteoblasts. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etidronate Disodium","conceptCode":"C831","definition":"A synthetic therapeutic diphosphonate analogue of endogenous pyrophosphate. As a member of the family of drugs known as bisphosphonates, etidronate disodium differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis.  This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption.  Etidronate may also directly stimulate bone formation by osteoblasts. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2972C1E6-9866-54DE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29750184-347E-0EED-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"Zometa or Zoledronate Acid","valueDescription":"Zoledronate","ValueMeaning":{"publicId":"2576643","version":"1","preferredName":"Zoledronate","longName":"2576643","preferredDefinition":"A drug that belongs to the family of drugs called bisphosphonates. It is used to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zoledronic Acid","conceptCode":"C1699","definition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F870-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29750184-348A-0EED-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2007-02-14","deletedIndicator":"No"},{"value":"An intravenous bisphosphonate of which you don't remember the name","valueDescription":"An intravenous bisphosphonate of which you don't remember the name","ValueMeaning":{"publicId":"2597234","version":"1","preferredName":"An intravenous bisphosphonate of which you don't remember the name","longName":"2597234","preferredDefinition":"An intravenous bisphosphonate of which you don't remember the name","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29750755-019A-0F92-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"297507D9-BC5C-04C1-E044-0003BA3F9857","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ONEDATA","dateModified":"2007-02-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2973E581-50D6-0AC5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2857180","version":"1","longName":"Type of Category","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812084","version":"1","longName":"Diagnostic","context":"NIDCR"},{"publicId":"2812085","version":"1","longName":"Preventive","context":"NIDCR"}]},{"publicId":"2857182","version":"1","longName":"Protocol Forms","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812041","version":"1","longName":"NIDCR","context":"NIDCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Have you EVER received any of","type":"Preferred Question Text","description":"Have you EVER received any of the following drugs intravenously (IV)","url":null,"context":"NIDCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"297515E5-93E5-114E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-14","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-14","modifiedBy":"ALAIS","dateModified":"2011-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}